(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue - 2Meet the astronauts about to make history on flight around the moon
- 3Munich Security Conference chief defends inviting AfD lawmakers
- 4Wolf bites woman in a shopping area in Germany's 2nd-biggest city
- 5The Best Competitors of the 21st Hundred years
- Want to make America healthy again? Stop fueling climate change
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- Move. Cheer. Dance. Do the wave. How to tap into the collective joy of 'we mode'
- How Mars 'punches above its weight' to influence Earth's climate
- Sun storms are powered by a magnetic engine 16 Earths deep, study finds
- Overlooked infertility care should be part of national health services, says WHO
- Revealing the Specialty of Food Matching: Improving Culinary Encounters
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
